Skip to main content

It's Time To Understand CAR-T Therapy For B-Cell Lymphoma: Earlier Indications Coming To A Community Near You

Part 1 of 4 in a series on: The Evolving Role of CAR T-cell Therapy for R/R B-cell Lymphomas: Improving Access and Outcomes

Click Here to Participate 

CE Activity Release Date: February 24, 2022
CE Activity Expiration Date: April 8, 2023 
Time to Complete Activity: 60 minute

 

Target Audience

This CE activity is intended for community-based hematologists-oncologists, fellows, NPs, PAs, nurses, pharmacists, navigators, social workers, and case managers engaged in the care of patients with R/R B-cell lymphomas.

 

Description

Through interactive discussion among CAR-T experts and a community-based oncologist, this activity provides practical information on how CAR T-cell therapy works, benefits, risks and updates on treatment, which patients may be candidates for CAR-T, action items for patient referral, and strategies and resources to help community practices.  Videos, animations and key learning points address clinical challenges with interprofessional perspectives to foster meaningful change. 

 

Educational Objectives

After completing this CE activity, the participant should be better able to:

  • Evaluate the benefits and risks of CAR T-cell therapy in relation to those of other treatments 
  • Identify patients who are candidates for CAR T-cell therapy 
  • Interpret the clinical significance of new and emerging data regarding CAR T-cell therapy

 

Faculty/Hosts

Sergio A. Giralt, MD, FACP
Melvin Berlin Family Chair in Myeloma Research
Professor of Medicine
Weill Cornell Medical College
Deputy Head, Division of Hematologic Malignancies
Attending Physician, Adult BMT Service 
Memorial Sloan Kettering Cancer Center
New York, NY

Sanjay K. Juneja, MD
Hematology, Medical Oncology
Chief of Oncology Line            
Baton Rouge General Hospital
Mary Bird Perkins Cancer Center
Baton Rouge, LA

Rayne H. Rouce, MD, BS
Associate Professor
Department of Pediatrics
Texas Children’s Cancer Center for Cell and Gene Therapy
Baylor College of Medicine
Houston, TX

Guest
Stephen J. Schuster, MD

Professor of Medicine, University of Pennsylvania 
Robert and Margarita Louis-Dreyfus Professor of CLL and Lymphoma
Director, Lymphoma Program and Lymphoma Translational Research 
Abramson Cancer Center, University of Pennsylvania
Philadelphia, PA

 

Educational Partner Statement

This activity is developed with our educational partner, Medical Learning Institute, Inc.

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society.   Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is certified for 1.0 credit/contact hours for physicians, registered nurses, pharmacists, physician assistants, social workers and case managers.

 

Support Statement

This activity is supported by an independent educational grant from Bristol Myers Squibb.

 

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. 
 

 

For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at ProfEducation@LLS.org